2 patient evaluations for Daclizumab

May 17, 2010 (Started Mar 03, 2007)

  • Effectiveness
    Major (for Participate in clinical trial)
  • Side effects
    Mild (rash or skin problems)
  • Adherence
    Always
  • Burden
    Somewhat hard to take
Dosage: 1 other Monthly
Advice & Tips: Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.
Cost: < $25 monthly
Side effects: rash or skin problems

Apr 13, 2010 (Started Mar 03, 2007)

  • Effectiveness
    Major (for Participate in clinical trial)
  • Side effects
    Mild (rash or skin problems)
  • Adherence
    Always
  • Burden
    Very hard to take
Dosage: 1 other Monthly
Advice & Tips: Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.
Cost: < $25 monthly
Side effects: rash or skin problems

Feb 16, 2010 (Started Mar 03, 2007)

  • Effectiveness
    Major (for Participate in clinical trial)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 1 other Monthly
Advice & Tips: Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.
Cost: < $25 monthly
Side effects: rash or skin problems

  • 1 helpful mark

Feb 12, 2010 (Started Feb 06, 2008)

  • Effectiveness
    Can't tell (for multiple sclerosis)
  • Side effects
    None
  • Adherence
    Never taken as prescribed
  • Burden
    Not at all hard to take
Dosage: 5 mg Monthly
Advice & Tips: Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus faucibus turpis sed mi maximus mattis.

Jan 12, 2010 (Started Feb 06, 2008)

  • Effectiveness
    Major (for multiple sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 5 mg Monthly

  • 0 helpful marks
Last updated:
Showing 2 of 2 patient evaluations for Daclizumab